Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health and During Acute Vaso-Occlusive Crisis

Next Previous
Trial Profile

A Phase 1/2 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline Health and During Acute Vaso-Occlusive Crisis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apadamtase alfa (Primary)
  • Indications Sickle cell anaemia; Vaso-occlusive crisis
  • Focus Adverse reactions
  • Acronyms RAISE-UP
  • Sponsors Shire

Most Recent Events

  • 12 Dec 2023 Results (n=19) presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 27 Nov 2023 According to a Takeda media release, topline data from this trial will be presented at the 65th American Society of Hematology (ASH) Annual Meeting.
  • 28 Nov 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top